20197-86-8

Usage

Uses

Used in Pharmaceutical Industry:
2-CHLORO-6,7-DIMETHOXY-3H-QUINAZOLIN-4-ONE is used as a reactant for the synthesis of Alogliptin, a potent and selective inhibitor of the serine protease dipeptidyl peptidase IV (DPP-IV). Alogliptin is an important drug used in the treatment of type 2 diabetes, as it helps to control blood sugar levels by increasing the levels of insulin and decreasing the levels of glucagon in the body. The compound's role in the synthesis of Alogliptin highlights its significance in the development of therapeutic agents for managing diabetes.

Upstream product

• 27631-29-4 2-chloro-6,7-dimethoxy-3H-quinazolin-4-one 

Downstream Products

• 20198-40-7 6,7-dimethoxy-2-(N-phenylamino)quinazolin-4-one 
• 441065-08-3 2-(1-benzyl-1,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-6,7-dimethoxy-3H-quinazolin-4-one 
• 441065-09-4 6,7-dimethoxy-2-(1-m-tolyl-1,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-3H-quinazolin-4-one 
• 441065-09-4 6,7-Dimethoxy-2-(1-m-tolyl-1,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-1H-quinazolin-4-one 
• 129112-53-4 6,7-Dimethoxy-2-(4-methyl-piperazin-1-yl)-4-phenoxy-quinazoline 
• 769158-08-9 2-((2-chloro-6,7-dimethoxy-4-oxoquinazolin-3(4H)-yl)methyl)benzonitrile 
• 16175-61-4 2-(Dimethylamino)-6,7-dimethoxy-3,4-dihydro-4-chinazolinon 
• 105150-92-3 6,7-Dimethoxy-2-[3-(3-piperidin-1-ylmethyl-phenoxy)-propylamino]-3H-quinazolin-4-one 
• 20198-38-3 2-benzylamino-6,7-dimethoxy-3H-quinazolin-4-one 
• 100448-62-2 4-(6,7-Dimethoxy-4-oxo-3,4-dihydro-quinazolin-2-ylamino)-benzoic acid 
• 828242-08-6 6,7-dimethoxy-2-[methyl-(3-pyrrolidin-1-yl-benzyl)-amino]-1H-quinazolin-4-one 

Relevant academic research and scientific papers

ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 INHIBITORS,COMPOSITIONS AND USES THEREOF

The present invention relates to compounds of Formula (I), methods of using the compounds as ENPP1 inhibitors, and pharmaceutical compositions comprising such compounds.The compounds are useful in treating cancers and infectious diseases.

Discovery of alogliptin: A potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV

Alogliptin is a potent, selective inhibitor of the serine protease dipeptidyl peptidase IV (DPP-4). Herein, we describe the structure-based design and optimization of alogliptin and related quinazolinone-based DPP-4 inhibitors. Following an oral dose, these noncovalent inhibitors provide sustained reduction of plasma DPP-4 activity and a lowering of blood glucose in animal models of diabetes. Alogliptin is currently undergoing phase 111 trials in patients with type 2 diabetes.

Pyrimidinone compounds

This invention relates to treating inflammatory and immune diseases with certain pyrimidinone compounds that bind to CXCR3 receptors. The pyrimidinone compounds are covered by the formula (I) shown below. Each variable is defined in the specification.

Process development and scale-up of a selective α1- adrenoceptor antagonist

A synthetic route to a potent and selective α-1-adrenergic receptor antagonist has been developed and demonstrated in a pilot plant. The route has been used in two pilot plant campaigns and has produced RO3203546 in 2.3 and 12.0 kg batch sizes. The first pilot plant campaign focused primarily on the end-game of the process with particular emphasis on the development of a method to isolate the active pharmaceutical ingredient (API). The second pilot plant campaign allowed front-end process improvements to be demonstrated. The reiterative process improvements resulted in an economical process with improved throughput and product quality when compared to the original discovery synthesis.

Structure-activity relationships of novel 2-substituted quinazoline antibacterial agents

High-throughput screening of in-house compound libraries led to the discovery of a novel antibacterial agent, compound 1 (MIC: 12-25 μM against S. pyogenes). In an effort to improve the activity of this active compound, a series of 2-substituted quinazolines was synthesized and evaluated in several antibacterial assays. One such compound (22) displayed improved broad- spectrum antibacterial activity against a variety of bacterial strains. This molecule also inhibited transcription/translation of bacterial RNA, suggesting a mechanism for its antibiotic effects. Structure-activity relationship studies of 22 led to the synthesis of another 24 compounds. Although some of these molecules were found to be active in bacterial growth assays, none were as potent as 22. Compound 22 was tested for its ability to cure a systemic K. pneumonia infection in the mouse and displayed moderate effects compared with a control antibiotic, gentamycin.